Literature DB >> 16961428

Mechanism of action of agents used in attention-deficit/hyperactivity disorder.

Timothy E Wilens1.   

Abstract

Several medications have been demonstrated effective in treating individuals with attention-deficit/hyperactivity disorder (ADHD). There appears to be some commonality in the physiologic mechanisms of action of these agents relevant to the treatment of ADHD. Either direct or indirect attenuation of dopamine and norepinephrine neurotransmission appears related to both the stimulant and nonstimulant medications efficacious in ADHD. However, important differences exist both between and within the specific classes of agents. Elucidating the various mechanisms of action of ADHD medications may lead to better choices in matching potential response to the characteristics (e.g., genotype) of individuals.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16961428

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  34 in total

Review 1.  Understanding attention-deficit/hyperactivity disorder from childhood to adulthood.

Authors:  Timothy E Wilens; Thomas J Spencer
Journal:  Postgrad Med       Date:  2010-09       Impact factor: 3.840

2.  Role of aberrant striatal dopamine D1 receptor/cAMP/protein kinase A/DARPP32 signaling in the paradoxical calming effect of amphetamine.

Authors:  Francesco Napolitano; Alessandra Bonito-Oliva; Mauro Federici; Manolo Carta; Francesco Errico; Salvatore Magara; Giuseppina Martella; Robert Nisticò; Diego Centonze; Antonio Pisani; Howard H Gu; Nicola B Mercuri; Alessandro Usiello
Journal:  J Neurosci       Date:  2010-08-18       Impact factor: 6.167

3.  Preclinical evaluation of reconsolidation blockade by clonidine as a potential novel treatment for posttraumatic stress disorder.

Authors:  Karine Gamache; Roger K Pitman; Karim Nader
Journal:  Neuropsychopharmacology       Date:  2012-08-08       Impact factor: 7.853

Review 4.  Lifestyle use of drugs by healthy people for enhancing cognition, creativity, motivation and pleasure.

Authors:  L-S Camilla d'Angelo; George Savulich; Barbara J Sahakian
Journal:  Br J Pharmacol       Date:  2017-05-12       Impact factor: 8.739

5.  A randomized trial of edivoxetine in pediatric patients with attention-deficit/hyperactivity disorder.

Authors:  Daniel Y Lin; Christopher J Kratochvil; Wen Xu; Ling Jin; Deborah N D'Souza; William Kielbasa; Albert J Allen
Journal:  J Child Adolesc Psychopharmacol       Date:  2014-05       Impact factor: 2.576

6.  Improvement in depression scores after 1 hour of light therapy treatment in patients with seasonal affective disorder.

Authors:  Gloria M Reeves; Gagan Virk Nijjar; Patricia Langenberg; Mary A Johnson; Baharak Khabazghazvini; Aamar Sleemi; Dipika Vaswani; Manana Lapidus; Partam Manalai; Muhammad Tariq; Monika Acharya; Johanna Cabassa; Soren Snitker; Teodor T Postolache
Journal:  J Nerv Ment Dis       Date:  2012-01       Impact factor: 2.254

7.  Adolescent D-amphetamine treatment in a rodent model of ADHD: Pro-cognitive effects in adolescence without an impact on cocaine cue reactivity in adulthood.

Authors:  Chloe J Jordan; Danielle M Taylor; Linda P Dwoskin; Kathleen M Kantak
Journal:  Behav Brain Res       Date:  2015-10-20       Impact factor: 3.332

8.  Norepinephrine transporter and catecholamine-O-methyltransferase gene variants and attention-deficit/hyperactivity disorder symptoms in adults.

Authors:  W Retz; M Rösler; C Kissling; S Wiemann; R Hünnerkopf; A Coogan; J Thome; C Freitag
Journal:  J Neural Transm (Vienna)       Date:  2007-11-12       Impact factor: 3.575

9.  Do college students improve their grades by using prescription stimulants nonmedically?

Authors:  Amelia M Arria; Kimberly M Caldeira; Kathryn B Vincent; Kevin E O'Grady; M Dolores Cimini; Irene M Geisner; Nicole Fossos-Wong; Jason R Kilmer; Mary E Larimer
Journal:  Addict Behav       Date:  2016-07-19       Impact factor: 3.913

10.  Profile of sexual and genitourinary treatment-emergent adverse events associated with atomoxetine treatment: a pooled analysis.

Authors:  Angelo Camporeale; Kathleen Ann Day; Dustin Ruff; Jody Arsenault; David Williams; Douglas K Kelsey
Journal:  Drug Saf       Date:  2013-08       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.